Sensitizing tumor cells to ferroptotic cell death by targeting Nrf2/ARE signaling pathway has been regarded as a promising synergistic strategy with chemoradiotherapy or immunotherapy [33–35]. This evidence concerns the gene NFE2L2 and neoplasm.